MILIND JAVLE to Drug Resistance, Neoplasm
This is a "connection" page, showing publications MILIND JAVLE has written about Drug Resistance, Neoplasm.
Connection Strength
0.138
-
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807.
Score: 0.069
-
Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer. 2016 12 01; 122(23):3657-3666.
Score: 0.053
-
A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. Cancer. 2018 10 01; 124(19):3890-3899.
Score: 0.016